SEC Tracker
Get the app

Frazier Lifesciences Acquisition

Frazier Lifesciences Acquisition Q3 FY22: net loss $4.8M

Form
10-Q
Filed
Period
Importance
Notable
Document
10-Q

Key figures from this report

These are the numbers Frazier Lifesciences Acquisition reported for Q3 FY22, the quarter ended Sep 30, 2022, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Net income−$4.8M−376% from $1.7M in Q3 FY2110-Q income statement, on EDGAR
  2. Cash and cash equivalents$376K−41% from $636K in Q3 FY2110-Q balance sheet, on EDGAR
  3. Cash from operations−$240KAgainst −$154K in Q3 FY2110-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters

View on EDGAR

Open in the app

Get an email when Frazier Lifesciences Acquisition files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Same SIC code (6770) and public float not reported.

  1. AEI CapForce II Investment AEIB
  2. AIS Holdings Group AIDG
  3. Aimfinity Investment Corp. I AIMTF
  4. APx Acquisition Corp. I APXIF
  5. Aquaron Acquisition AQUC

Data on this page was fetched . The filing on SEC.gov is the record.